Carl Blau
Hematology & Oncology · Seattle, WANPI 1881779619
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,860 of the $15,448 with a category attached, or 83.2%. 10 manufacturers reported payments, led by Gilead at 57.8% of the total. Reporting peaked in 2023 at $8,967 and has fallen 96.5% since, to $314 in 2025.
Across 21 payments — averaging $735.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$9K
- GSK$5K
- Johnson & Johnson$1K
- Adaptive Biotechnologies Corporation$227
- AstraZeneca$135
- Caris MPI, Inc.$126
- plus $201 from 4 others
Across 13 payments — averaging $101,785 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.2M
- GSK$122K
- Caris MPI, Inc.$1K
What the payments were for
- Consulting fees$12,86083%
- Travel & lodging$1,73411%
- Food & beverage$8546%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 11 | $8,928 |
| GSK | 1 | $4,550 |
| Johnson & Johnson | 1 | $1,280 |
| Adaptive Biotechnologies Corporation | 2 | $227 |
| AstraZeneca | 1 | $135 |
| Caris MPI, Inc. | 1 | $126 |
| Rigel Pharmaceuticals, Inc. | 1 | $125 |
| Sanofi | 1 | $39 |
| Pfizer | 1 | $25 |
| Genentech, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DARZALEX$1,280
- clonoSEQ$163
- CALQUENCE$135
- MI CANCER SEEK$126
- Tavalisse$125
How this compares
$15,448 in reported general payments places this provider in the 80th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.